Ask AI
Risk Stratification in ET and PV

CME

Risk Stratification in Polycythemia Vera and Essential Thrombocythemia: Applying Prognostic Scoring Systems in Practice

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: February 03, 2026

Expiration: August 02, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this module, Joan How, MD, explores current risk stratification models used in essential thrombocythemia (ET) and polycythemia vera (PV), highlighting how clinical, laboratory, and molecular factors are utilized to estimate the risks of thrombosis and disease progression as well as survival and to inform treatment decisions.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with PV or ET do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting

A 54-year-old woman was recently diagnosed with ET. The patient has no history of thrombosis, and molecular testing reveals a JAK2 V617F mutation.

What is this patient’s risk category for thrombosis per the revised International Prognostic Score of Thrombosis (IPSET) score?